Welcome to our dedicated page for Unicycive Therapeutics SEC filings (Ticker: UNCY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a 200-page biotech filing packed with clinical trial minutiae and cash-runway calculations is tough鈥攅specially when Unicycive Therapeutics鈥� renal drug pipeline means every 10-K hides critical FDA milestones. If you have ever wondered, 鈥淗ow do I follow Unicycive Therapeutics insider trading Form 4 transactions or locate their latest quarterly earnings report 10-Q filing?鈥�, you are not alone.
Stock Titan solves that problem. Our platform delivers AI-powered summaries that explain complex disclosures in plain language, flagging trial outcomes, patent extensions, and liquidity updates the moment Unicycive Therapeutics posts an 8-K. Need the big picture? The annual report 10-K simplified section highlights R&D spend and risk factors. Looking for specifics? Form 4 insider transactions appear in real-time, so you can track executive stock moves before the market reacts. Key long-tail resources include:
- Unicycive Therapeutics SEC filings explained simply鈥攅very form, every footnote
- Unicycive Therapeutics earnings report filing analysis that links quarter-over-quarter trial costs to cash burn
- Under颅standing Unicycive Therapeutics SEC documents with AI鈥攏o jargon required
Investors use these insights to monitor drug-development timelines, compare segment expenses, and gauge dilution risk from future capital raises. Whether you need Unicycive Therapeutics executive stock transactions Form 4, a proxy statement executive compensation breakdown, or Unicycive Therapeutics 8-K material events explained, our real-time feed and expert commentary keep you ahead. Save hours, stay informed, and make better decisions about this kidney-focused biotech鈥攁ll in one place.
Unicycive Therapeutics, Inc. (Nasdaq: UNCY) filed a Form 8-K dated 30 June 2025 to disclose a material regulatory development and preliminary liquidity data.
The company announced that the U.S. Food and Drug Administration issued a Complete Response Letter (CRL) for its New Drug Application covering oxylanthanum carbonate (OLC), proposed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. The CRL indicates that the agency will not approve the NDA in its current form; specific deficiencies were not disclosed in the filing. The news was disseminated through a press release furnished as Exhibit 99.1 and incorporated into Items 2.02 and 8.01 of this report.
Management also provided a preliminary, unaudited cash figure of approximately $20.7 million as of 30 June 2025. The company has not yet completed its condensed consolidated financial statements for the quarter ended 30 June 2025, and its independent registered public accounting firm has performed no review procedures on this estimate. Accordingly, the figure may change when full second-quarter results are finalized.
The filing contains no additional earnings data, major transactions, or financing events. Exhibits include the referenced press release (Ex. 99.1) and the Inline XBRL cover page file (Ex. 104). Investors should monitor future disclosures for the FDA鈥檚 requested actions and for finalized Q2 results.
Unicycive Therapeutics (NASDAQ: UNCY) has announced a 1-for-10 reverse stock split effective June 18, 2025, at 4:01 PM ET. The company's common stock began trading on a split-adjusted basis on the Nasdaq Capital Market on June 20, 2025, maintaining its "UNCY" symbol but with a new CUSIP number.
Key details of the reverse split:
- Reduced outstanding shares from 126,409,281 to approximately 12,768,239
- No fractional shares issued - fractional interests rounded up to the next whole share
- Proportionate adjustments made to stock options, warrants, and Series A-2 prime preferred stock conversion prices
- No change to authorized shares or par value
- No material change to stockholders' percentage ownership or voting power
The reverse split follows stockholder approval on June 9, 2025, which authorized the board to implement a split ratio between 1-for-2 and 1-for-20 before June 9, 2026. This corporate action affects multiple registration statements on Forms S-3 and S-8 currently on file with the SEC.
FAQ
What is the current stock price of Unicycive Therapeutics (UNCY)?
What is the market cap of Unicycive Therapeutics (UNCY)?
What is the primary focus of Unicycive Therapeutics?
What are the main products in Unicycive's pipeline?
How does Unicycive Therapeutics differentiate itself in the biotechnology sector?
What steps does the company take to ensure clinical safety and efficacy?
How important is intellectual property to Unicycive Therapeutics?
What is the significance of Renazorb in the treatment landscape?
How does Unicycive contribute to the field of renal therapeutics?
Who are the key stakeholders that benefit from Unicycive's research?
